CYP19A1 and neoplasm: These results are in line with the recent study by of Leyland-Jones et al. [11] that investigated CYP19A1 tumor genotype data in relation to endocrine treatment response in the BIG 1–98 trial, but in contrast to a previous study on genomic CYP19A1 genotypes regarding the risk of recurrence in AI-treated patients [13].